IMA
ImageneBio Inc
NASDAQ · USHealthcareBiotechnology
$5.73+6.51%
Price as of Jul 20, 2026
IMA financials
ImageneBio Inc financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $800.0K | $3.5M | $9.2M | $15.6M |
| Cost of revenue | $1.0M | $1.5M | $1.0M | $64.3M |
| Gross profit | -$233.0K | $3.5M | $8.1M | -$48.7M |
| Operating expenses | $48.2M | $40.5M | $83.6M | $22.2M |
| Operating income | -$48.5M | -$37.0M | -$75.4M | -$70.9M |
| Net income | -$45.3M | -$36.6M | -$68.2M | -$68.8M |
| EBITDA | -$44.7M | -$35.0M | -$67.3M | -$68.0M |
| Basic EPS | $-10.76 | $-1.02 | $-1.63 | $-1.90 |
| Diluted EPS | $-10.76 | $-1.02 | $-1.63 | $-1.90 |
| Balance sheet | ||||
| Cash & equivalents | $35.0M | $39.4M | $119.9M | $59.9M |
| Total assets | $153.0M | $141.5M | $192.1M | $172.3M |
| Total liabilities | $19.8M | $15.6M | $22.3M | $25.3M |
| Stockholders’ equity | $133.1M | $125.9M | $169.8M | $147.0M |
| Total debt | $10.0M | $7.5M | $10.7M | $5.7M |
| Net debt | -$25.0M | -$31.9M | -$109.2M | -$54.2M |
| Cash flow | ||||
| Operating cash flow | -$47.8M | -$46.0M | -$79.7M | -$74.1M |
| Capital expenditure | $0.00 | $0.00 | -$414.0K | -$1.4M |
| Free cash flow | -$47.8M | -$46.0M | -$80.2M | -$75.5M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | -$663.0K | $0.00 |